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Neurodegenerative diseasesAdiponectin is an anti-atherogenic protein secreted by adipose cells that improves insulin sensitivity. Notably,
adiponectin receptors are expressed in the brain, suggesting that adiponectin signaling disruption may impact
neurologic function. Recently, studies have demonstrated the association of adiponectin levels with cerebrovas-
cular disorders and neurodegenerative diseases (NDDs), and these results have drawn signiﬁcant attention. In
this review, we discuss the association between the adiponectin levels and the incidence, progression, and
prognosis of cerebrovascular disorders and NDDs. We describe the controversial issues surrounding current
studies and present our hypothesis concerning the possible mechanism underlying adiponectin function in
neurological disorders. Finally, we explicate obstacles preventing clinical adiponectin administration, including
available routes of drug delivery and the central nervous system regulation of adiponectin. Collectively, the
data assembled herein serve as a comprehensive reference regarding the role of adiponectin in neurological
disorders to support the future clinical potential of adiponectin as a therapeutic agent.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Neurological diseases constitute a group of disorders affecting the
spinal cord and the brain. Cerebrovascular diseases and neurodegener-
ative diseases (NDDs), which carry high morbidity and mortality, are
two major types of neurological diseases that are presently garnering
signiﬁcant attention [1,2]. Cerebrovascular diseases induce brain
dysfunction via cerebral ischemia and hemorrhage (the leading causes
of adult disability and death [2]). Treatments for cerebral ischemia and
hemorrhage remain limited. Tissue plasminogen activator (tPA) is the
only treatment approved by the FDA for cerebral ischemia, and tPA
must be administered within 3 h of ischemia symptom onset [3]. Limit-
ed by low recanalization rates, b5% of patients receive rapid interven-
tion [4]. Both medical and surgical treatments are available for
cerebral hemorrhage, but outcomes remain unsatisfactory [5–7]. There
is an urgent need for new therapeutic targets and biomarkers that canThe Fourth Military Medical
. Lau), yanqu1974@126.compredict the incidence and the prognosis of cerebral ischemic andhemor-
rhagic events. Neurodegeneration is the umbrella term covering the
progressive loss of neuronal structure or function, resulting in irrevers-
ible brain damage. The incidence of NDDs, includingAlzheimer's disease
(AD), multiple sclerosis (MS), Parkinson's disease (PD), Huntington's
disease (HD) and amyotrophic lateral sclerosis (ALS), is increasing at
an alarming rate worldwide [1,8,9]. However, the etiologies of NDDs
are not well understood. No cures exist for these disorders, and new
therapeutic targets and biomarkers are urgently needed.
Secreted by adipose cells, adiponectin increases insulin sensitivity,
possesses anti-atherogenic properties, and regulates glucose levels
and fatty acid breakdown [10,11]. Low adiponectin levels are an inde-
pendent risk factor for the development of metabolic syndrome [10,
12] and diabetes mellitus [11,13]. Additionally, hypoadiponectinemia
and adiponectin gene polymorphisms are risk factors for coronary
heart disease and cardiovascular disease [14]. However, the relationship
between the adiponectin levels and neurological disorders is unclear.
The receptors for adiponectin, AdipoR1 and AdipoR2, are prominently
expressed in the brain [15], suggesting that adiponectin signaling
may be intricately related to neurologic function and, consequently,
neurological pathology. Recently, marked attention has been directed
toward the association of adiponectin with cerebrovascular disorders
and NDDs. Based on these studies, we discuss the association of the
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incidence, progression and prognosis of cerebrovascular disorders and
NDDs.
In the current review, we summarize the latest progress regarding
the association of adiponectin with cerebrovascular disorders and
NDDs. First, we review the discovery of adiponectin, its structure, and
its known receptors. Next, we discuss the known associations of
adiponectin with cerebrovascular disorders and NDDs. Finally, we
identify several controversial issues concerning these associations and
explicate the future prospects of the clinical application of adiponectin
for treating neurological disorders. We aimed to compile a comprehen-
sive reference concerning the current information concerning
adiponectin and neurological disorders; we hope that this information
will aid in the design of further experimental research advancing the
therapeutic potential of adiponectin against neurologic disease.1.1. Discovery of adiponectin
In 1995, Scherer et al. ﬁrst characterized adiponectin as a novel 30-
kDa secretory protein (Acrp30) expressed in differentiating 3 T3-L1
adipocytes [16] (Fig. 1). In 1996, adiponectin was described in mouse
and ratmodels as “GBP28” (mRNA transcripts of gelatin-bindingprotein
of 28 kDa size), “apM1” (adiposemost abundant gene transcript 1), and
“AdipoQ” (a protein found highly expressed in adipose tissue) [17–19].
The human adipose-speciﬁc and most abundant gene transcript, apM1,
was isolated [18], and the apM1 gene product was termed adiponectin
[20]. Arita et al produced monoclonal and polyclonal antibodies against
human adiponectin and developed an enzyme-linked immunosorbent
assay (ELISA) to quantify the plasma adiponectin concentration; these
tools produced dramatic breakthroughs in this ﬁeld of study [20].
Signiﬁcant work was subsequently performed by others to deter-
mine the connections between adiponectin and visceral adiposity,
insulin resistance, and vascular diseases [21,22]. In 2007, Lara-Castro
et al. [11] identiﬁed adiponectin as a highly expressed transcript
in preadipocytes differentiating into adipocytes. These studies ultimate-
ly demonstrated the pleiotropic effects of adiponectin, indicating
adiponectin as an attractive therapeutic target for obesity-related
conditions.
Previous studies assured a promising future for adiponectin in terms
of therapeutic applications for pathophysiological conditions. However,
further studies revealed the nature of adiponectin physiology to be
complex. Despite its adipose origin, adiponectin expression decreased
in obesity, and adiponectin administration induced weight loss. The
mechanism by which adiponectin expression decreases during obesity
is not fully understood [23]. As evidence substantiating the association
between adiponectin and the metabolic/cardiovascular complicationsFig. 1. The discovery of adiponectin. The ﬂow chart desof obesity has accumulated [23–25], new relationships between
adiponectin and adaptive immunity, inﬂammation, cancer, and neuro-
logical disease have been discovered [26–29]. In the current review,
we direct our focus to the association of adiponectin with neurological
disease.1.2. Structure and receptors of adiponectin
Adiponectin is a 244-amino-acid polypeptide encoded by the
ADIPOQ gene in humans [18] that has previously been referred to as
GBP-28, apM1, AdipoQ, or Acrp30. Adiponectin possesses four distinct
structural domains [30]. The ﬁrst domain is a short signal sequence
targeting the protein for secretion outside the cell. The second domain
is a short region that is variable between species, and the third domain
is a 65-amino acid collagenous region. Interestingly, the ﬁnal globular
domain possesses stronger signaling activity in isolation than the full
protein [31]. Overall, the ADIPOQ gene shows similarity to complement
1Q factors (C1Qs) [30]. When the three-dimensional structure of the
globular region was determined, a striking similarity to TNFα was
observed, despite their unrelated protein sequences [30].
Adiponectin binds to numerous receptors. Two receptors (AdipoR1
and AdipoR2) share homology to G protein–coupled receptors; a third
receptor, CDH13, is similar to cadherin family proteins [32,33]. AdipoR1
and AdipoR2 are predicted to contain seven transmembrane helices
with a topology opposite to that of G-protein–coupled receptors. Their
seven-transmembrane helices, which are conformationally distinct
from those of G-protein–coupled receptors, enclose a large cavity in
which three conserved histidine residues coordinate with a zinc ion.
The zinc-binding structure may play a role in adiponectin-stimulated
adenosine monophosphate (AMP)-activated protein kinase (AMPK)
phosphorylation and uncoupling protein 2 (UCP2) upregulation. The
primary biological effects of adiponectin occur via its stimulation of
AdipoR1 and AdipoR2, which increase the activities of 5′AMP and
peroxisome proliferator-activated receptor (PPAR), respectively [34].
The overall structures, large internal cavities and extracellular faces of
AdipoR1 and AdipoR2 are presented in Figs. 1, 4 and 5, respectively, in
the study by Hiroaki et al. [34]. AdipoR1 and AdipoR2 are distributed
throughout the bodywith varying tissue speciﬁcity and exhibit different
afﬁnities for the varying adiponectin isoforms. AdipoR1 is predominant-
ly located on skeletalmuscle and endothelial cells [35–37], and AdipoR2
is most highly expressed in the liver [32]. Recently, many studies have
demonstrated that AdipoR1 and AdipoR2 are also expressed in the
brain [15,38,39].
In turn, AdipoR1 and AdipoR2 target downstream AMPK and UCP2,
which serve as important cellular metabolic rate control points.
Adiponectin receptor expression correlates with the insulin levels. Thecribes main events in the history of adiponectin.
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particularly in skeletal muscle and adipose tissue [40,41]. Recent focus
has been directed toward adiponectin signaling regulation in the brain
[42,43].
1.3. Cerebrovascular diseases
Cerebrovascular diseases encompass pathologies concerning
interrupted vascular supply to the brain, causing injury and dysfunction.
In this section, we speciﬁcally focus on cerebral ischemic and hemor-
rhagic injury.
1.3.1. Cerebral ischemic injury
Cerebral ischemic injury is the most common cerebrovascular
disorder. The association between adiponectin and cerebral ischemia
remains unclear. The adiponectin levels change signiﬁcantly in ischemic
patients. Compared with controls, ischemic patients display signiﬁcant-
ly reduced serum adiponectin levels [44]. Moreover, no difference was
noted in the serum adiponectin level between patients experiencing
cerebral infarction and those with other atherosclerotic disorders
(such as arteriosclerosis obliterans or ischemic heart disease) [44].
During the acute phase of cerebral infarction, ischemic stroke patients,
display signiﬁcantly decreased adiponectin levels upon admission com-
pared to control subjects, but these levels in ischemic stroke patients
subsequently recover to basal levels [44,45]. The association between
adiponectin gene polymorphisms and ischemic stroke risk has also
been examined. In a study of Han population women from northern
China, Chen et al. [46] demonstrated a relationship between the
rs2241766 variant in the adiponectin gene and ischemic stroke risk.
Furthermore, the GG genotype of rs266729 increases ischemic stroke
risk. This demonstration may aid in the early prediction of ischemic
stroke incidence and may contribute to early intervention for ischemic
stroke.
The circulating adiponectin concentration may even aid in diagnos-
ing and predicting the prognosis of various cerebral ischemia subtypes.
Symptomatic intracranial atherosclerosis is associated with lower
serum adiponectin levels than other ischemic stroke subtypes. Patients
with advanced intracranial atherosclerosis (deﬁned as one or more
additional lesions outside the symptomatic arterial territory) exhibit
lower serum adiponectin levels than those with isolated intracranial
atherosclerosis [47]. Kim et al. demonstrated that patients experiencing
large artery atherosclerosis (LAA) strokes display lower levels of serum
adiponectin than patients experiencing non-LAA strokes; this ﬁnding
suggested that the adiponectin levels may be used to stratify the
ischemic stroke severity subtype [48]. Additionally, the plasma
adiponectin levels may help to distinguish between stroke subtypes of
atherothrombotic and cardioembolic origin [49]. Together, these studies
support the further investigation of adipocytokines and their utility as
biomarkers for various heterogeneous stroke subtypes. Because the
adiponectin levels are associated with neurological severity and
functional outcome, adiponectin may be valuable for the prediction of
prognosis. Efstathiou et al. demonstrated that an adiponectin concen-
tration b4 μg/mL, a National Institutes of Health Stroke Scale score
N15, and coronary heart disease are independently associated with
mortality after a ﬁrst-ever ischemic stroke and that hypoadiponec-
tinemia is associated with increased 5-year mortality risk independent
of all other adverse predictors [50]. Kuwashiro et al. reported that
plasma adiponectin values may help predict neurological severity and
functional outcome in ischemic stroke patients [49].
Although hypoadiponectinemia is associated with increased
mortality after ischemic stroke, the causal role of adiponectin in ische-
mic stroke remains unknown. Usingmultiple regression analysis, Sasaki
et al. demonstrated that adiponectin is an independent factor that
contributes to cerebral infarction and that hypoadiponectinemia is
concomitantly involved in the pathogenesis of atherosclerosis in sub-
jects with cerebral infarction [51]. Nishimura et al. provided causalevidence that adiponectin exerts a cerebroprotective effect via an
endothelial nitric oxide synthase-dependent mechanism [43]. Chen
et al. [52] demonstrated that APN displays potent cerebroprotective
activity via an anti-inﬂammatory effect and that NF-κB is a key compo-
nent in this process. Employing a mouse model of transient unilateral
middle cerebral artery occlusion (tMCAO), Shen et al. demonstrated
that adiponectin overexpression attenuates ischemia-induced brain
atrophy and improves neurological function secondary to augmented
focal angiogenesis [42]. Furthermore, the AMPK signaling pathway
plays an important role in the upregulation of the angiogenic factor
VEGF. Despite its limitations, this study demonstrated that adiponectin
may be a potential molecular target for ischemic stroke therapy.
Interestingly, adiponectin overexpression reduces ischemic brain
injury and improves neurobehavioral functional recovery in aged
mice relative to youngmice, suggesting that adiponectinmay be of ben-
eﬁt to aged animals after ischemic stroke [53]. Despite moderate
associations between high-molecular weight (HMW) adiponectin and
cardiovascular disease and the observation that an altered plasma
adiponectin level is associated with cerebral ischemia incidence, there
is no evidence of an association between the HMW adiponectin levels
and the ischemic stroke incidence in postmenopausal women [54].
The variety of these studies and their results indicate that adiponectin
plays various roles in different populations, and this interesting
phenomenon warrants further study.
In conclusion, adiponectin decreases the incidence of cerebral
ischemia. The adiponectin levels change over time and during ischemia
development. Adiponectinmay serve as a biomarker for the diagnosis of
cerebral ischemia subtypes and may predict the recovery of neurobe-
havioral function. Moreover, adiponectin may serve as a molecular
target for ischemic stroke therapy.
1.3.2. Cerebral hemorrhagic injury
Cerebral hemorrhagic injury results from bleeding within the
brain parenchyma. Several studies have evaluated the association of
adiponectin with cerebral hemorrhage.
Takeuchi et al. determined the temporal proﬁle of the plasma
adiponectin levels in patients with subarachnoid hemorrhage who
experienced delayed cerebral ischemia [55]. The plasma adiponectin
concentrations in patients experiencing delayed cerebral ischemia
were signiﬁcantly lower than those in patients not experiencing
delayed cerebral ischemia [55]. Therefore, hypoadiponectinemia might
be associated with delayed cerebral ischemia and poor functional out-
come. In another study, the adiponectin concentration was an indepen-
dent indicator of early death but was not predictive of the Glasgow
Coma Scale (GCS) score or the hematoma volume [56]. The serum
adiponectin levels are closely related to cerebral microbleeds (CMBs),
and adiponectin may protect against the prevalence of CMBs [57].
Osuka et al. reported an interesting ﬁnding: after subarachnoid
hemorrhage (SAH), the cerebrospinal ﬂuid (CSF) contained signiﬁcantly
increased levels of adiponectin, resulting in the activation of AMPKα
and eNOS [58]. Moreover, adiponectin plays an important role in
preventing cerebral vasospasm via the AMPK/eNOS signaling pathway
[58]. Another study reported that adiponectin may play an anti-
inﬂammatory role after intracerebral hemorrhage [56].
In brief, low levels of adiponectin are associated with cerebral
hemorrhage, which subsequently results in delayed ischemia, mortality
and morbidity. However, the adiponectin levels increase after cerebral
hemorrhagic injury and potentially exert neuroprotective effects.
These complex ﬁndings concerning adiponectin in the setting of
cerebral hemorrhage must be investigated further.
1.4. NDDs
NDDs occur as a result of neurodegeneration and irreversible brain
damage. In this section, we discuss the association of adiponectin with
AD, MS, and PD (Table 1).
Table 1
The association between adiponectin and NDDs. NDDs, neurodegenerative diseases; AD, Alzheimer's disease; MS, multiple sclerosis; PD, Parkinson's disease; HD, Huntington's disease; IL,
interleukin; MPP, master production planning.
NDD Adiponectin levels Evidence First author, year, and reference no.
AD Increased Adiponectin levels are signiﬁcantly higher in mild cognitive impairment (MCI) and AD
patients than in controls.
Une et al., 2011 [61]
Increased There is a dramatic increase in the level of adiponectin in the blood of AD subjects
compared with that of controls.
Khemka et al., 2014 [62]
Increased In women, increased plasma adiponectin levels are an independent risk factor for the
development of both all-cause dementia and AD.
van Himbergen et al., 2012 [63]
No relevance In early AD patients, there is no signiﬁcant difference in the plasma adiponectin levels
compared with normal controls.
Bigalke et al., 2011 [64]
No relevance There is no signiﬁcant difference in the adiponectin levels between normal controls
and AD subjects.
Warren et al., 2012 [65]
Decreased The serum level of adiponectin is lower in APP Tg mice than in non-Tg mice. Kurata et al., 2013 [66]
Increased The changes in the serum levels of adiponectin in AD positively correlate with the
severity of dementia.
Khemka et al., 2014 [62]
Decreased Low adiponectin levels are associated with cognitive dysfunction. Teixeira et al., 2013 [59]
MS Decreased Decreased adiponectin levels, along with increased levels of IL-12p70 and IL-13, in
sera from MS patients compared with that from controls.
Musabak et al., 2011 [68]
Decreased Signiﬁcantly decreased serum levels of adiponectin in MS patients compared with
controls.
Beni et al., 2014 [69]
No relevance There are no differences in the adiponectin levels among subgroups of patients with
MS stratiﬁed according to the therapy regimen and a healthy control group.
Musabak et al., 2011 [68]
Increased Twins with MS displayed higher concentrations of adiponectin than their
asymptomatic co-twins.
Hietaharju et al., 2010 [70]
Decreased RRMS patients exhibit signiﬁcantly decreased adiponectin levels, a reduced
percentage of nTreg cells, and a reduced mean ﬂuorescence channel (MFC) of FoxP3.
Kraszula et al., 2012 [67]
Decreased Adiponectin-deﬁcient mice developed exacerbated EAE, including more severe CNS
inﬂammation, demyelination, and axon injury, and treatment with globular
adiponectin in vivo ameliorated EAE in a manner that is associated with an increase in
Treg cells.
Piccio et al., 2013[71]
PD No relevance Adiponectin is unaltered in PD. Aziz et al., 2011 [72]
No relevance The serum adiponectin levels in PD patients are similar to those in normal-weight,
healthy, young subjects.
Cassani et al., 2011 [73]
Decreased Treatment with recombinant adiponectin may suppress neurodegeneration by
modifying the metabolic pathway and may display therapeutic potential against
α-synucleinopathies.
Sekiyama et al., 2014 [74]
Decreased Adiponectin treatment attenuated the increase in the levels of reactive oxygen species
and nitric oxide and rescue the impairment in mitochondrial membrane potential
induced by the DJ-1L166P mutation.
Li et al., 2014 [75]
Decreased Acetaldehyde- and MPP + -induced apoptosis can be reversed by adiponectin
treatment.
Jung et al., 2006a; Jung et al., 2006b [76,77]
HD Decreased Higher mean adiponectin levels are associated with a greater degree of motor and
functional impairment in HD patients.
Aziz et al., 2010 [78]
Increased HD mice exhibit reduced levels of adiponectin. Phan et al., 2009 [79]
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AD, a chronic, progressive neurodegenerative disease, is responsible
for 60–70% of dementia cases [59,60]. The complete etiology of AD
remains unclear.
Une et al. [61] demonstrated a positive correlation between the
plasma and CSF adiponectin levels, which are signiﬁcantly higher in
patients with mild cognitive impairment (MCI) or AD than in controls.
The results of Khemka et al.[62] also showed a dramatic increase in
the level of adiponectin in the blood of AD subjects compared to that
of controls. In women, increased plasma adiponectin levels are an inde-
pendent risk factor for the development of both all-cause dementia and
AD [63]. However, Bigalke et al. measured the blood concentrations of
adiponectin in early AD patients and found no signiﬁcant differences
in the plasma adiponectin levels compared with normal controls [64].
Warren et al.[65] were also unable to demonstrate a signiﬁcant differ-
ence in the adiponectin levels between normal controls and AD sub-
jects. The serum adiponectin levels were lower in amyloid precursor
protein (APP) transgenic (Tg) mice than in non-Tg mice [66]. This
increase in the serum levels of adiponectin in AD positively correlates
with the severity of dementia [62]. Teixeira et al. [59] evaluatedwhether
the circulating adiponectin levels are predictive of the progression of
MCI to AD by comparing MCI/AD patients to cognitively healthy elders.
They concluded that low adiponectin levels are associated with
cognitive dysfunction, although the adiponectin concentration did notpredict future cognitive decline or the conversion to dementia.
Decreased adiponectin expression may serve as a surrogate marker of
the pathological process linking clinical comorbidities, inﬂammation,
and cognitive dysfunction in AD [66].
These studies suggest that adiponectin has a complex association
with AD and that the alteration of the adiponectin expression levels in
AD patients remains unclear. Based on the limited available evidence,
low adiponectin levels cannot predict the incidence or eventual
progression of AD. However, low levels of adiponectin are accompanied
by cognitive dysfunction in AD. Many future studies are needed to fully
understand the association between adiponectin and AD.
1.4.2. MS
MS is a chronic inﬂammatory disease of the brain and the spinal cord
[67]. As such, researchers have evaluated the association of adiponectin
with inﬂammatorymediators and cell types.Musabak et al. [68] demon-
strated decreased adiponectin levels, along with increased levels of
interleukin (IL)-12p70 and IL-13, in sera from MS patients compared
with that from controls, suggesting that the decline in the adiponectin
level may play a role in MS pathogenesis. Signiﬁcantly decreased
serum levels of adiponectin in MS were also found in another study
[69]. However, there were no differences in the adiponectin levels
between subgroups of MS patients stratiﬁed according to their therapy
regimen and a healthy control group [68]. Twins with MS displayed
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[70]. However, the adiponectin and adipsin levels in CSF did not
correlate with their levels in plasma[70]. Kraszula et al. [67] evaluated
adiponectin and natural regulatory T (nTreg) cells in patients with
relapsing–remitting MS (RRMS). RRMS patients were found to exhibit
signiﬁcantly decreased adiponectin levels, a reduced percentage of
nTreg cells, and reduced mean ﬂuorescence channel (MFC) of FoxP3,
suggesting that adiponectin plays a role in the anti-inﬂammatory
response and inhibits FoxP3 expression in RRMS patients. Piccio
et al.[71] demonstrated that adiponectin plays a protective role in
the experimental allergic encephalomyelitis (EAE) model of MS and
that this protective effect can be induced by immunization with
myelin antigens or by the transfer of myelin-speciﬁc T lymphocytes.
Adiponectin-deﬁcient mice developed worse EAE with more severe
CNS inﬂammation, demyelination, and axon injury [71]. Treatment
with globular adiponectin in vivo ameliorated EAE and was associated
with an increase in Treg cells [71]. These data indicated that adiponectin
is an important regulator of T-cell functions during EAE, suggesting a
new avenue of investigation for MS treatment.
In summary, MS patients displays altered levels of adiponectin, and
most studies support that this decline in adiponectin expression is
associated with the incidence of MS. Furthermore, treatment with
adiponectin can beneﬁt MS patients.
1.4.3. PD
PD is a neurodegenerative disease displaying primarilymotor symp-
toms. The pathology of PD involves thedopamine-generating substantia
nigra in the brain, although its mechanism and etiology are unclear.
Ahmad et al. [72] reported that adiponectin expression is unaltered in
PD. Another study demonstrated that the serum adiponectin levels in
PD patients are similar to those in normal-weight, healthy, young
subjects and are signiﬁcantly higher than those in aged-matched mor-
bidly obese subjects [73]. Data concerning the associations between
adiponectin and PD are currently contradictory, and this issue requires
additional investigation. However, treatment with recombinant
adiponectin may suppress neurodegeneration by modifying the
metabolic pathway and may display therapeutic potential against α-
synucleinopathies [74]. L166P mutant DJ-1 has been linked to a genetic
form of PD.Moreover, adiponectin treatment attenuated the increase in
the levels of reactive oxygen species and nitric oxide and rescued
the impairment in mitochondrial membrane potential induced by the
DJ-1L166P mutation [75]. The protective effects of adiponectin against
DJ-1L166P depend on AMPK activation, which is mediated by the
endosomal protein adaptor protein with phosphotyrosine binding,
pleckstrin homology domains and leucine zipper motif (APPL1) [75].
Jung et al [76,77] studied the protective effects of adiponectin on
human neuroblastoma SH-SY5Y cells; they found that acetaldehyde-
and master production planning (MPP) + -induced apoptosis was
prevented by adiponectin treatment via the induction of the expression
of anti-oxidant enzymes and the regulation of Bcl-2 and Bax expression.
These data suggest that adiponectin may serve as a potential target for
novel therapies against PD.
1.4.4. HD
HD is a hereditary neurodegenerative disorder caused by an
increased number of CAG repeats in the huntingtin gene. A hallmark
of HD is unintended weight loss, the cause of which is unknown. The
plasma levels and the diurnal rhythmicity of adiponectin is not signiﬁ-
cantly different between HD patients and controls. However, higher
mean adiponectin levels are associated with a greater degree of motor
and functional impairment in HD patients [78]. Interestingly, HD mice
exhibit reduced levels of adiponectin [79].
In conclusion, the understanding of the role of adiponectin in the
pathophysiology of various NDDs is currently in its infancy. The expres-
sion level of adiponectin in various NDDs such as AD, PD, MS and HD
remain unclear, but the alteration of adiponectin expression maycontribute to the incidence of NDDs via various mechanisms and to a
varying extent. According to this limited evidence, the supplementation
and activation of adiponectin protect against NDDs. Additionally,
amyotrophic lateral sclerosis (ALS) is a debilitating disease with varied
etiology characterized by rapidly progressiveweakness,muscle atrophy
and fasciculations, muscle spasticity, dysarthria, dysphagia and
dyspnea; however, few studies have reported on the association of
adiponectin with ALS. Whether and how adiponectin contributes to
the incidence or progression of NDDs require further study and
validation.
1.5. Discussion and future prospects
Adiponectin is a protein that is secreted by adipose cells. Previous
studies have demonstrated that adiponectin increases insulin sensitivi-
ty, displays anti-atherogenic activity, and regulates the levels of glucose
and fatty acids [10,11]. Recently, the association of adiponectin with
neurological diseases, including both cerebrovascular diseases and
NDDs, has attracted attention [48,53,55,61,64,67,72]. However, the
exact role of adiponectin in the CNS is unclear. Numerous studies of
adiponectin have been conducted in cerebrovascular diseases and
NDDs. Based on the limited evidence, low levels of adiponectin are
associatedwith the incidence of neurological disorders. A compensatory
increase in the adiponectin levels exerts a neuroprotective effect.
However, persistent hypoadiponectinemia is associatedwith secondary
lesions and increased morbidity and mortality (Fig. 2). Evidence
supporting this hypothesis is documented in cases of cerebral hemor-
rhage but is limited in cases of cerebral ischemia and NDDs. The
alterations in the adiponectin concentrations after cerebral ischemic
injury warrant further study. Additionally, future studies evaluating
the speciﬁc association (or lack thereof) between adiponectin and
NDDs (particularly MS, PD, ALS, and HD) will be of great potential
diagnostic, prognostic, and therapeutic value for the innumerable
patients suffering from these diseases.
Numerous studies have examined the association between
adiponectin and neurological diseases [48,53,55,61,64,67,72]. Most of
the available data are clinical [44,45] and do not fully provide insight
regarding causality. Previous studies have demonstrated that different
circulatory adiponectin concentrations play distinct roles in disease
processes via multiple mechanisms [20]. Nevertheless, whether ﬂuctu-
ating systemic concentrations of adiponectin exert variable CNS
effects is unclear. To date, no studies have investigated the impact of
hypoadiponectinemia on the CNS. Neurological disorders have complex
pathophysiologies [80–82]. Previous studies have demonstrated
that adiponectin may perform a neuroprotective function in the
CNS via mechanisms that remain to be elucidated. As additional
details concerning the anti-atherogenic, anti-inﬂammatory, and anti-
remodeling properties of adiponectin have emerged [27,83–85], it has
become apparent that adiponectin may exert neuroprotective effects
via multiple mechanisms. A meta-analysis reported that the circulating
total adiponectin level is not related to the risk of stroke but that after
controlling for metabolic factors that positively correlate with the
adiponectin levels, the adiponectin levels are directly related to stroke
risk [86]. Among the subtypes of cerebral ischemia, intracranial athero-
sclerosis is associatedwith lower adiponectin levels than other ischemic
stroke subtypes [47–49]. Thus, atherosclerotic plaques may serve as a
centralmediator of the neuroprotective effects of adiponectin, including
its anti-inﬂammatory and angiogenic activities, suggesting an associa-
tion of adiponectin with neurologic disorders [42,52] (Fig. 2).
Unfortunately, the available literature supporting adiponectin as a
promising therapeutic target for the reduction of injury caused by
neurologic disorders and sequelae lacks causal conﬁrmation and
mechanistic evidence [51]. Because adiponectin is a protein, orally ad-
ministered adiponectin cannot be absorbed [87]. Currently, adiponectin
is administered via intravenous or intraperitoneal injection [87,88]. The
blood–brain barrier (BBB) is formed by endothelial cells and tight
Fig. 2. Potential links between adiponectin and neurological disorders. Adiponectin can reduce inﬂammation and promotes angiogenesis, thus exerting neuroprotective effects. However, low
levels of adiponectin might induce inﬂammation and inhibit angiogenesis, ﬁnally resulting in the incidence of neurological disorders. On the other hand, there may exist a feedback to
elevate levels of adiponectin in response to neurological disorders. Moreover, adiponectin may be augmented via receptor agonist and lifestyle interventions, such as diet and exercise.
Simulating adiponectin peptide is can cross the blood–brain barrier and may be used to therapeutically treat and prevent neurological disorders.
1892 Y. Yang et al. / Biochimica et Biophysica Acta 1852 (2015) 1887–1894junctions, which form capillary walls. It has been demonstrated 98% of
small molecule drugs and 100% of large molecule drugs, including
peptides, recombinant proteins, monoclonal antibodies, genes, and
short interfering RNAs, cannot cross the BBB [89,90]. The delivery of
adiponectin (30 kDa) into the brain parenchyma has also been ham-
pered by the presence of the BBB. Previous studies have shown that
many recombinant protein drugs can be introduced to avoid the short-
comings of gene therapy for clinical applications, including neurogenin-
2 (Ngn2) and interferon [91,92]. The Ngn2 protein can be regulated in
the CNS simply via the delivery of recombinant Ngn2 fusion protein
[91]. Based on these exciting ﬁndings, we hope to develop a stimulatory
adiponectin peptide with a molecular weight of less than 2000 Da. This
predicted stimulatory peptide should be not only capable of traversing
the blood–brain barrier but also beneﬁcial for the treatment and
prevention of neurological disorders in the future.We can also direct at-
tention to adiponectin receptor agonists. Recently, a small molecule
adiponectin receptor agonist has been discovered. This agonist has
been suggested as a novel therapeutic agent for the treatment of
obesity-associated type 2 diabetes in an experimental mouse model
[93]. Osmotin, an antifungal stress response protein that belongs to
the pathogenesis-related (PR)-5 family, confers tolerance to both biotic
and abiotic stresses in plants. However, osmotin acts similar to the
mammalian hormone adiponectin in various in vitro and in vivo
models. Adiponectin and osmotin do not share sequence similarity at
the amino acid level, but interestingly, these two receptor-binding
proteins display a similar structural and functional properties [94].
Osmotin may act as an agonist of mammalian adiponectin in humans.
This possibility indicates numerous attractive candidates for the
regulation of adiponectin receptors in the CNS. Some studies have also
demonstrated that the serum adiponectin levels can be increased via
pharmaceutical and lifestyle interventions such as diet and exercise [95,
96]. Most importantly, there is a positive correlation between the
plasma and CSF levels of adiponectin [61]. If adiponectin in the CSF
can be inﬂuenced by pharmaceutical and lifestyle interventions,
patients with neurologic disorders may efﬁcaciously beneﬁt.
There remains a signiﬁcant gap in our understanding of many
phenomena related to adiponectin. For example, adiponectin overex-
pression beneﬁts aged mice to a greater extent than young mice,
suggesting age-speciﬁc effects of adiponectin [53]. This phenomenon
is also observed in postmenopausal women [54], reminding us that
there is signiﬁcant work to be done before widespread clinical deploy-
ment of adiponectin can commence.
Our understanding of adiponectin and its associations with neuro-
logic disorders remains in its infancy. As researchers invested in the
study of neurovascular science and clinicians treating an ever growing
patient population in need, we are hopeful that future dedicated
research on the relationship between adiponectin and neurological
disorders will yield promising ﬁndings.Disclosures
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